Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee

Ir Med J. 2008 Jan;101(1):6-7.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adalimumab
  • Advisory Committees*
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects*
  • Antibiotic Prophylaxis
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / administration & dosage*
  • Antirheumatic Agents / adverse effects*
  • Antitubercular Agents / administration & dosage*
  • Etanercept
  • Humans
  • Immune System Diseases / etiology
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / adverse effects
  • Infliximab
  • Ireland
  • Practice Guidelines as Topic*
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Tuberculosis / drug therapy
  • Tuberculosis / etiology*
  • Tuberculosis / prevention & control
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Antitubercular Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept